Physician

April Ann Erwin, MD

According to 2025 Medicare claims, April Erwin, MD (NPI: 1194976670) practices neurology in the Salt Lake City-Murray, UT market, with the plurality of this provider's patient population coming from Salt Lake, UT. This provider's primary affiliated billing organization is DR JOHN FOLEY LLC (NPI: 1437330974; TIN: 010759642) and primary practice location at 84103-2895.

Erwin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 211 traditional Medicare patients, billed 77,102 HCPCS/CPT codes, and received $1,493,205 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,764 prescription claims across 340 beneficiaries totaling $1,425,422 in drug costs, led by Kesimpta Pen (Ofatumumab). 2022 DME data shows 11 claims. Open Payments data shows 282 records totaling $216,011. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $87,183 to $1,493,205. In contrast, Part D prescription costs have fallen sharply in recent years, from $5,022,924 to $1,425,422. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $34,151 and ending at $65,957.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	494	1,430	$87,183
2016	542	1,463	$101,083
2017	530	2,093	$80,527
2018	585	1,133	$87,675
2019	515	1,138	$72,400
2020	412	728	$54,308
2021	339	591	$49,982
2022	309	1,108	$47,734
2023	187	56,804	$1,175,341
2024	211	77,102	$1,493,205

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	473	5,506	$5,022,924
2016	522	6,606	$6,080,487
2017	548	7,272	$8,324,351
2018	560	6,219	$8,419,768
2019	521	5,422	$7,595,722
2020	562	6,205	$7,923,298
2021	608	6,608	$7,397,528
2022	610	7,016	$7,492,229
2023	615	2,950	$3,356,569
2024	340	1,764	$1,425,422

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	53	$2,087
2017	N/R	35	$959
2018	N/R	44	$1,289
2019	N/R	50	$1,150
2020	N/R	53	$3,858
2021	N/R	N/R	N/R
2022	N/R	11	$572
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	142	217	$81
96413	Administration of chemotherapy into vein, 1 hour or less	41	53	$55
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	78	235	$45
J2323	Injection, natalizumab, 1 mg	87	65,436	$18
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	97	109	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kesimpta Pen	Ofatumumab	24	702	$218,968
Glatiramer Acetate	Glatiramer Acetate	24	672	$82,025
Dalfampridine Er	Dalfampridine	56	2,040	$16,282
Nurtec Odt	Rimegepant Sulfate	15	443	$14,353
Linzess	Linaclotide	14	420	$7,534

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	268	$41,748	EMD Serono, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	14	$174,263	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for April Ann Erwin, MD?

Tedicare shows public-source Medicare data for April Ann Erwin, MD (NPI 1194976670), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does April Ann Erwin, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to April Ann Erwin, MD?

April Ann Erwin, MD is linked to DR JOHN FOLEY LLC (billing NPI 1437330974) in the available physician profile data.

Does April Ann Erwin, MD have Open Payments data?

April Ann Erwin, MD has 282 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.